shenzhen salubris pharmaceuticals co., ltd.-九游会

 shenzhen salubris pharmaceuticals co., ltd.-九游会

the marketing application of sal0107 for the treatment of primary hypertension was accepted

publisher: views:

latest progress

recently, salubris announced that nmpa has accepted the marketing application of its self-developed sal0107.

sal0107 is an arb/ccb compound preparation for treating patients with primary hypertension with poor blood pressure control after allisartan or amlodipine mono-therapy.

after the launch of the product, it will form a strategic synergy with xinlitan (allisartan isoproxil tablets), a class 1.1 antihypertensive marketed drug, further enrich the innovative product pipeline in cardiovascular area, cover a broader population of hypertensive patients, provide patients with more medication options, and enhance the comprehensive competitiveness of salubris in the field of chronic disease.


basic information

drug name: sal0107

application information: registration and marketing authorization for domestically produced drugs 

registry classification: 2.3 category

drug type: chemical

acceptance number: cxhs2200061  

acceptance instructions: according to the provisions of article 32 of the administrative licensing law of the people's republic of china, it is decided to accept it after examination.